The approval of Boehringer Ingelheim's anticancer drug afatinib highlights the growing enthusiasm for once-shunned irreversible kinase inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Sanderson, K. Irreversible kinase inhibitors gain traction. Nat Rev Drug Discov 12, 649–651 (2013). https://doi.org/10.1038/nrd4103
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4103
- Springer Nature Limited
This article is cited by
-
The long and short non-coding RNAs modulating EZH2 signaling in cancer
Journal of Hematology & Oncology (2022)
-
The impact of structural biology in medicine illustrated with four case studies
Journal of Molecular Medicine (2018)
-
Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists
Scientific Reports (2016)
-
Divergent synthesis and identification of the cellular targets of deoxyelephantopins
Nature Communications (2016)
-
Protein tyrosine phosphatases as potential therapeutic targets
Acta Pharmacologica Sinica (2014)